Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Noninvasive Genetic Prenatal Testing Possible Using Rare Fetal Cells

XTALKS VITALS NEWS

Prenatal

RareCyte’s technology is capable of detecting gene deletions between two and three million base pairs in length, which is an improvement over current technologies.

Share this!

October 26, 2016 | by Sarah Hand, M.Sc.

Rare fetal cells which can be isolated from a pregnant woman’s blood sample, could be used to develop noninvasive genetic prenatal tests. The research – which was conducted at Baylor College of Medicine and RareCyte, Inc. – was published in the journal, Prenatal Diagnosis.

“Fetal cells were first reported in the circulation of pregnant women more than 40 years ago, and people have been hoping since that time to be able to use them for prenatal diagnosis,” said senior study author Dr. Arthur Beaudet, Chair of Molecular and Human Genetics at Baylor. “With the emergence of RareCyte's platform technology for the identification of rare circulating cells and the retrieval of single cells, this is now possible.”

RareCyte, a life sciences company that offers tools able to analyze single cells from liquid biopsies and tissue samples, has developed a specialized platform capable of isolating rare fetal cells. The technology utilizes an automated image scanner to identify these fetal cells, coupled with a precision needle to extract them from the sample.

“Our goal in this project was to determine whether it was possible to collect trophoblasts present in the mother's circulation in numbers sufficient for further genetic analysis,” said Beaudet. Trophoblasts form the major part of the placenta and contain all of the genetic information from the fetus.

According to RareCyte, while two teaspoons of maternal blood contains hundreds of billions of red blood cells, only 20 to 40 fetal cells may be present in the sample. Using their imaging technology, the researchers were regularly able to extract three to 10 fetal cells which could be further analyzed using tools including next generation DNA sequencing.



“We are pleased to be working with Dr. Beaudet and his team at Baylor on this critical project,” said Ron Seubert, chairman and CEO of RareCyte. “This is a milestone achievement in prenatal research and for RareCyte.”

As certain invasive forms of prenatal testing carry risks for both mother and baby, some chose to perform noninvasive methods, including cell-free DNA testing. Unfortunately, these technologies have limitations in terms of the resolution of DNA changes that can be detected. RareCyte’s technology is capable of detecting gene deletions between two and three million base pairs in length, which is an improvement over current technologies.

The company believes that this test could offer comparable information to that obtained through amniocentesis and chorionic villus sampling. According to Beaudet, this test could be available to parents seeking prenatal diagnosis, in the next one or two years.


Keywords: Prenatal Testing, Next Generation Sequencing, Liquid Biopsy


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News


Lung Cancer Recurrence Could Be Better Detected Using Biomarker Blood Test

March 24, 2017 - The results of a recent prospective clinical trial found that a biomarker blood test could detect lung cancer recurrence a full six months before imaging methods could spot the disease.

Featured In: Biotech News


Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News

 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.